CO2017008809A2 - Compuestos de benzoxaborol y uso de los mismos - Google Patents

Compuestos de benzoxaborol y uso de los mismos

Info

Publication number
CO2017008809A2
CO2017008809A2 CONC2017/0008809A CO2017008809A CO2017008809A2 CO 2017008809 A2 CO2017008809 A2 CO 2017008809A2 CO 2017008809 A CO2017008809 A CO 2017008809A CO 2017008809 A2 CO2017008809 A2 CO 2017008809A2
Authority
CO
Colombia
Prior art keywords
compounds
ch2ch2ch3
ch2ch3
benzoxaborol compounds
mycobacterial
Prior art date
Application number
CONC2017/0008809A
Other languages
English (en)
Spanish (es)
Inventor
M R K Alley (Dickon)
Jacob J Plattner
Xianfeng Li
David Barros-Aguirre
Ilaria Giordano
Vincent Hernandez
Carlos Alemparte-Gallardo
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017008809(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CO2017008809A2 publication Critical patent/CO2017008809A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CONC2017/0008809A 2015-02-12 2017-08-29 Compuestos de benzoxaborol y uso de los mismos CO2017008809A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15382054 2015-02-12
EP15382055 2015-02-12
EP15382056 2015-02-12
PCT/IB2016/050775 WO2016128948A1 (en) 2015-02-12 2016-02-12 4 -substituted benzoxaborole compounds and uses thereof

Publications (1)

Publication Number Publication Date
CO2017008809A2 true CO2017008809A2 (es) 2017-11-10

Family

ID=55409879

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2017/0008809A CO2017008809A2 (es) 2015-02-12 2017-08-29 Compuestos de benzoxaborol y uso de los mismos
CONC2017/0008816A CO2017008816A2 (es) 2015-02-12 2017-08-29 Compuestos de benzoxaborol y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CONC2017/0008816A CO2017008816A2 (es) 2015-02-12 2017-08-29 Compuestos de benzoxaborol y usos de los mismos

Country Status (36)

Country Link
US (3) US10774096B2 (https=)
EP (2) EP3256479B1 (https=)
JP (2) JP2018506540A (https=)
KR (2) KR20170117158A (https=)
CN (2) CN107548398A (https=)
AU (3) AU2016217508A1 (https=)
BR (2) BR112017017213A2 (https=)
CA (2) CA2976308A1 (https=)
CL (2) CL2017002059A1 (https=)
CO (2) CO2017008809A2 (https=)
CR (2) CR20170371A (https=)
CY (1) CY1123687T1 (https=)
DK (1) DK3256479T3 (https=)
DO (2) DOP2017000188A (https=)
EA (2) EA036516B1 (https=)
ES (1) ES2821951T3 (https=)
HR (1) HRP20201597T1 (https=)
HU (1) HUE051113T2 (https=)
IL (2) IL253865A0 (https=)
LT (1) LT3256479T (https=)
MA (2) MA41494B1 (https=)
MX (2) MX379057B (https=)
MY (1) MY194004A (https=)
NZ (1) NZ734379A (https=)
PE (2) PE20171432A1 (https=)
PH (2) PH12017501427A1 (https=)
PL (1) PL3256479T3 (https=)
PT (1) PT3256479T (https=)
RS (1) RS60885B1 (https=)
SG (2) SG11201706510YA (https=)
SI (1) SI3256479T1 (https=)
SM (1) SMT202000565T1 (https=)
TW (2) TW201702250A (https=)
UA (1) UA120527C2 (https=)
WO (2) WO2016128949A1 (https=)
ZA (1) ZA201705456B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
RS63461B1 (sr) 2017-05-08 2022-08-31 Glaxosmithkline Ip Dev Ltd Sanfetrinem ili njegova so ili estar za upotrebu u lečenju mikobakterijske infekcije
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
WO2020041200A1 (en) 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
EP4384527A4 (en) * 2022-06-23 2025-09-03 Micurx Pharmaceuticals Inc PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
CA3239096A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
EP0947498B1 (en) 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
EP2343304B1 (en) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
EP1856113B1 (en) 2005-03-08 2016-01-06 Agency for Science, Technology and Research Chiral bisoxazoline catalysts
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010080558A1 (en) 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
ES2710105T3 (es) * 2010-04-07 2019-04-23 Glaxosmithkline Llc Proceso para preparar benzoxaboroles
SI3251678T1 (sl) * 2010-09-07 2022-01-31 Anacor Pharmaceuticals, Inc. Derivati benzoksaborola za zdravljenje bakterijskih okužb
JP6031122B2 (ja) * 2011-12-22 2016-11-24 ミクウルク ファーマシューティカルズ,インコーポレイテッド 抗微生物療法のための三環式ホウ素化合物
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof

Also Published As

Publication number Publication date
US10774096B2 (en) 2020-09-15
TW201643173A (zh) 2016-12-16
DOP2017000189A (es) 2018-02-15
WO2016128948A1 (en) 2016-08-18
CN107531730A (zh) 2018-01-02
CL2017002059A1 (es) 2018-03-16
EP3256480A1 (en) 2017-12-20
SG11201706511TA (en) 2017-09-28
US20180044353A1 (en) 2018-02-15
PH12017501428A1 (en) 2018-01-15
DOP2017000188A (es) 2017-09-15
IL253864A0 (en) 2017-09-28
AU2016217508A1 (en) 2017-09-28
HRP20201597T1 (hr) 2020-12-25
LT3256479T (lt) 2020-12-28
NZ734379A (en) 2023-06-30
BR112017017213A2 (pt) 2018-04-03
AU2016217507B2 (en) 2019-03-14
BR112017017211A2 (pt) 2018-04-03
RS60885B1 (sr) 2020-11-30
US20180037595A1 (en) 2018-02-08
MX2017010414A (es) 2018-05-11
SMT202000565T1 (it) 2020-11-10
CR20170372A (es) 2017-10-19
IL253865A0 (en) 2017-10-31
EP3256479B1 (en) 2020-07-29
PL3256479T3 (pl) 2021-06-14
DK3256479T3 (da) 2020-11-02
KR20170117158A (ko) 2017-10-20
CL2017002060A1 (es) 2018-03-16
CA2976030A1 (en) 2016-08-18
CY1123687T1 (el) 2022-03-24
SG11201706510YA (en) 2017-09-28
EA201791671A1 (ru) 2018-02-28
JP2018506540A (ja) 2018-03-08
EA036516B1 (ru) 2020-11-18
MA41495A (fr) 2017-12-19
PE20171432A1 (es) 2017-09-26
AU2016217507A1 (en) 2017-09-28
CN107531730B (zh) 2020-08-07
TWI730953B (zh) 2021-06-21
CN107548398A (zh) 2018-01-05
EP3256479A1 (en) 2017-12-20
US11214582B2 (en) 2022-01-04
JP2018506538A (ja) 2018-03-08
MA41494B1 (fr) 2020-10-28
EA201791667A1 (ru) 2018-02-28
US20210053996A1 (en) 2021-02-25
MX379057B (es) 2025-03-10
MY194004A (en) 2022-11-07
HUE051113T2 (hu) 2021-01-28
ZA201705456B (en) 2019-10-30
CR20170371A (es) 2018-01-22
MA41494A (fr) 2017-12-19
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
WO2016128949A1 (en) 2016-08-18
CO2017008816A2 (es) 2017-11-10
AU2020256369A1 (en) 2020-11-12
JP6771472B2 (ja) 2020-10-21
TW201702250A (zh) 2017-01-16
BR112017017211B1 (pt) 2023-04-25
IL253864B (en) 2021-07-29
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
CA2976308A1 (en) 2016-08-18
PE20171348A1 (es) 2017-09-13
PH12017501427A1 (en) 2018-01-15
CA2976030C (en) 2023-09-26
ES2821951T3 (es) 2021-04-28
KR20170117156A (ko) 2017-10-20

Similar Documents

Publication Publication Date Title
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
CR20160064A (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
PE20211775A1 (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso
CO2019012473A2 (es) Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos
PA8799101A1 (es) Compuestos tienopirimidina y pirazolopirimidina y su uso como inhibidores de quinasa mtor y quinasa p13
AR048813A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY33961A (es) Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
UY35293A (es) Isotiazoles sustituidos con amino
SV2018005657A (es) "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
CL2023003921A1 (es) Inhibidores de transglutaminasas
CL2023003979A1 (es) Inhibidores de las transglutaminasas
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
PE20200887A1 (es) Forma a-i de monoacetato de (s)-7-(4-(1-(metilsulfonil)piperidin-4-il)fenil)-n-(morfolin-2-ilmetil)pirido[3,4-b]pirazin-5-amina
ECSP24007534A (es) Inhibidores de transglutaminasas
UY36662A (es) Compuestos de benzoxaborol y uso de los mismos
BR112013016984A2 (pt) composições e métodos de uso de formas cristalinas de análogos de wortmanina
CL2022002037A1 (es) Uso de un compuesto inhibidor de fgfr; forma sólida amorfa; proceso para preparar el compuesto (div. sol. n° 202002839).
JO3673B1 (ar) مكونات البنزوكسابورول ثلاثي الحلقات واستخداماتها